Actinium-225 in targeted alpha-particle therapeutic applications.
Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer.
Department of Molecular Pharmacology and Chemistry, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue,New York, NY 10065, USA.
David A
DA
Scheinberg
Michael R
MR
McDevitt
D000186:Actinium / Q000737:chemistry / Q000627:therapeutic use*; D000512:Alpha Particles / Q000627:therapeutic use*; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D008081:Liposomes; D023421:Models, Animal; D009369:Neoplasms / Q000532:radiotherapy*; D016499:Radioimmunotherapy; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D000911:Antibodies, Monoclonal; D008081:Liposomes; D019275:Radiopharmaceuticals; D000186:Actinium